Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
5.37M
-
Number of holders
-
7
-
Total 13F shares, excl. options
-
79.7K
-
Shares change
-
+69.7K
-
Total reported value, excl. options
-
$273K
-
Value change
-
+$239K
-
Number of buys
-
6
-
Price
-
$3.43
Significant Holders of Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP) as of Q4 2024
7 filings reported holding NEUP - Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share as of Q4 2024.
Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP) has 7 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 79.7K shares
of 5.37M outstanding shares and own 1.48% of the company stock.
Largest 7 shareholders include Lynx1 Capital Management LP (45.8K shares), JANE STREET GROUP, LLC (13.3K shares), Merck & Co., Inc. (10K shares), BANK OF AMERICA CORP /DE/ (6.48K shares), UBS Group AG (2.98K shares), RHUMBLINE ADVISERS (1.11K shares), and MORGAN STANLEY (7 shares).
This table shows the top 7 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.